<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01674842</url>
  </required_header>
  <id_info>
    <org_study_id>12-283</org_study_id>
    <nct_id>NCT01674842</nct_id>
  </id_info>
  <brief_title>Cisplatin + RT for Triple Negative Breast Cancer</brief_title>
  <official_title>A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients
      with ER negative, PR negative and HER2 negative breast cancer who have undergone
      breast-conserving surgery or mastectomy.

      Primary objective: To assess the safety, tolerability, and maximum tolerated dose (MTD) of
      cisplatin when given concurrently with radiation therapy for participants with Stage II or
      III breast cancer who have undergone breast conserving surgery or mastectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I dose escalation study of cisplatin and radiation to determine the toxicity
      of this combined treatment and establish an MTD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Cisplatin w/ Radiation</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the maximum tolerated dose of cisplatin when given concurrently with radiation therapy for participants with Stage II or III breast cancer who have undergone breast conserving surgery or mastectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local recurrence at 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>To assess local recurrence at 5-years in participants receiving cisplatin concurrently with radiation, as compared with historic controls receiving radiation without concurrent chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>To assess long-term toxicity in participants receiving cisplatin concurrently with radiation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin + Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin concurrently with radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Once daily, Monday - Friday for six weeks</description>
    <arm_group_label>Cisplatin + Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Intravenously, once weekly for six weeks</description>
    <arm_group_label>Cisplatin + Radiation Therapy</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary tumor is triple negative breast cancer

          -  Breast-conserving surgery or mastectomy with surgical excision of all gross disease
             with negative surgical margins

          -  Pathologic or clinical stage II or III disease

          -  At least 3 week interval from last chemotherapy administration/breast surgery to
             radiation (no more than 8 weeks)

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Prior radiation to breast or ipsilateral regional nodes

          -  Ongoing therapy with other investigational agents

          -  Hormonal therapy

          -  Significant co-morbidity

          -  Pathologic complete response following preoperative chemotherapy

          -  Biopsy proven metastatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer R Bellon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Bellon, MD</last_name>
    <phone>6176323591</phone>
    <email>jbellon@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J Isakoff, MD PHD</last_name>
      <phone>617-726-6500</phone>
      <email>sisakoff@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bellon, MD</last_name>
      <phone>617-632-3591</phone>
      <email>jbellon@partners.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Bellon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bellon, MD</last_name>
      <phone>617-632-3591</phone>
      <email>jbellon@partners.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Bellon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber at Milford</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Lingos, MD</last_name>
      <phone>508-488-3835</phone>
      <email>tlingos@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber at South Shore Hospital</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Lingos, M.D.</last_name>
      <phone>781-624-4700</phone>
      <email>tlingos@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2012</study_first_submitted>
  <study_first_submitted_qc>August 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jennifer Bellon</investigator_full_name>
    <investigator_title>Principal Invstigator</investigator_title>
  </responsible_party>
  <keyword>Triple negative</keyword>
  <keyword>Stage II</keyword>
  <keyword>Stage III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

